Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Seattle Genetics (SGEN)

No earlier versions found for this Subject.

Return to Seattle Genetics (SGEN)

S-1 filed 11/20/00. JP Morgan, CIBC, BoA.

We discover and develop monoclonal antibody, or mAb, based drugs to treat cancer and related diseases. Using our mAb-based technologies and our expertise in cancer, we have assembled a portfolio of drug candidates targeted to many types of human cancers. We utilize our mAb-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. We are currently testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers. SGN-15 is in three phase II clinical trials in combination with the chemotherapy drug Taxotere. SGN-10 is in two phase I clinical trials, one as a single agent and the other in combination with Taxotere. We have five preclinical product candidates being developed to treat patients with solid tumors, melanoma or hematologic malignancies. One of our preclinical product candidates, SGN-14, is being developed by Genentech pursuant to a license agreement. In addition to providing us with the means to discover and develop mAb-based product candidates ourselves, our technologies allow us to partner with other companies also developing mAbs.